A retrospective, observational study of ramucirumab and in combination with docetaxel within US community oncology settings in this recently emerged post-ICI/PDC patient population
Latest Information Update: 14 Oct 2021
At a glance
- Drugs Docetaxel (Primary) ; Ramucirumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 14 Oct 2021 New trial record
- 14 Sep 2021 Results presented at the 2021 World Conference on Lung Cancer.